- Language: English
- 443 Pages
- Published: January 2012
- Region: Global
Generics in Canada
- Published: August 2013
- Region: Canada
- 34 pages
Generics in Canada industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Canada generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Canadian generics market had total revenues of $5.4bn in 2012, representing a compound annual growth rate (CAGR) of 6.6% between 2008 and 2012.
- Market consumption volume increased with a CAGR of 5.2% between 2008-2012, to reach a total of 60.1% of total pharma volume in 2012.
- The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $6.7bn by the end of 2017.
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Canada
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Canada
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Canada generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Canada economy
Key Questions Answered
What was the size of the Canada generics market by value in 2012?
What will be the size of the Canada generics market in 2017?
What factors are affecting the strength of competition in the Canada generics market?
How has the market performed over the last five years?
What are the main segments that make up Canada's generics market? SHOW LESS READ MORE >
Market value forecast
Market volume forecast
Market value forecast
Market volume forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Related MarketLine research
LIST OF TABLES
Table 1: Canada generics market value: $ million, 2008–12
Table 2: Canada generics market volume: % of total pharma volume, 2008–12
Table 3: Canada generics market geography segmentation: $ million, 2012
Table 4: Canada generics market value forecast: $ million, 2012–17
Table 5: Canada generics market volume forecast: % of total pharma volume, 2012–17
Table 6: Apotex, Inc.: key facts
Table 7: Mylan Inc.: key facts
Table 8: Mylan Inc.: key financials ($)
Table 9: Mylan Inc.: key financial ratios
Table 10: Sandoz International GmbH: key facts
Table 11: Teva Pharmaceutical Industries Limited: key facts
Table 12: Teva Pharmaceutical Industries Limited: key financials ($)
Table 13: Teva Pharmaceutical Industries Limited: key financial ratios
Table 14: Canada size of population (million), 2008–12
Table 15: Canada gdp (constant 2000 prices, $ billion), 2008–12
Table 16: Canada gdp (current prices, $ billion), 2008–12
Table 17: Canada inflation, 2008–12
Table 18: Canada consumer price index (absolute), 2008–12
Table 19: Canada exchange rate, 2008–12
LIST OF FIGURES
Figure 1: Canada generics market value: $ million, 2008–12
Figure 2: Canada generics market volume: % of total pharma volume, 2008–12
Figure 3: Canada generics market geography segmentation: % share, by value, 2012
Figure 4: Canada generics market value forecast: $ million, 2012–17
Figure 5: Canada generics market volume forecast: % of total pharma volume, 2012–17
Figure 6: Forces driving competition in the generics market in Canada, 2012
Figure 7: Drivers of buyer power in the generics market in Canada, 2012
Figure 8: Drivers of supplier power in the generics market in Canada, 2012
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Canada, 2012
Figure 10: Factors influencing the threat of substitutes in the generics market in Canada, 2012
Figure 11: Drivers of degree of rivalry in the generics market in Canada, 2012
Figure 12: Mylan Inc.: revenues & profitability
Figure 13: Mylan Inc.: assets & liabilities
Figure 14: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 15: Teva Pharmaceutical Industries Limited: assets & liabilities
Apotex, Inc., Mylan Inc., Sandoz International GmbH and Teva Pharmaceutical Industries Limited